文献速递复苏、休克与脓毒症创伤与烧伤

雌激素(17α-炔雌醇-3-硫酸盐)降低多发伤与失血性休克猪模型死亡率

An estrogen (17α-ethinyl estradiol-3-sulfate) reduces mortality in a swine model of multiple injuries and hemorrhagic shock.
PubMed 文献 · J Trauma Acute Care Surg · 2022-01-01
一句话结论在多发伤合并失血性休克猪模型中,伤后给予17α-炔雌醇-3-硫酸盐0.3和1 mg/kg可降低6小时死亡风险并改善心肌收缩力,支持开展人体创伤临床试验。

研究采用良好实验室规范,对30头雄性未去势猪(25-50 kg)造成胫骨骨折、肺挫伤和30%控制性失血1小时,伤后随机给予EES 0、0.3、1、3、5 mg/kg,不进行复苏,观察6小时或至死亡。6小时生存率分别为0%、50%、33.3%、16.7%、0%;Cox回归显示0.3 mg/kg组死亡风险比0.22(95%CI 0.05-0.93)和1 mg/kg组0.24(95%CI 0.06-0.89)显著降低,3和5 mg/kg组未显著降低。1 mg/kg组平均生存时间246分钟,较0 mg/kg组96分钟显著延长(p=0.04)。作者认为这些发现支持在人类创伤患者中开展临床试验。

要点

  • 在多发伤合并失血性休克猪模型中,伤后给予EES 0.3 mg/kg和1 mg/kg使6小时死亡风险显著降低,死亡风险比分别为0.22(95%CI 0.05-0.93)和0.24(95%CI 0.06-0.89)。
  • EES 3 mg/kg和5 mg/kg未显著降低死亡风险,风险比分别为0.49(95%CI 0.15-1.64)和0.46(95%CI 0.14-1.47)。
  • 1 mg/kg组平均生存时间246分钟,较0 mg/kg组96分钟显著延长(p=0.04,t检验)。
  • 给药后1小时,0.3和1 mg/kg组心肌收缩力较伤后显著升高(p=0.003和p<0.001),3和5 mg/kg组无变化,对照组显著降低(p=0.022)。
  • 作者认为该结果支持在人类创伤患者中开展临床试验。

适用人群与场景

  • 雄性未去势猪,体重25-50 kg,接受胫骨骨折、肺挫伤和30%控制性失血1小时。
  • 伤后给药,不进行液体复苏,观察6小时或至死亡。

处置流程与药物剂量

  • 伤后给予EES,剂量分组为0(对照)、0.3、1、3、5 mg/kg,给药途径原文未写明。
  • 不进行液体复苏,观察6小时或至死亡。

研究设计与关键结果

  • 研究类型:动物实验(猪模型),30头雄性未去势猪随机分为5组,每组6头。
  • 6小时生存率:0 mg/kg组0%,0.3 mg/kg组50%,1 mg/kg组33.3%,3 mg/kg组16.7%,5 mg/kg组0%。
  • Cox比例风险回归:0.3 mg/kg组死亡风险比0.22(95%CI 0.05-0.93),1 mg/kg组0.24(95%CI 0.06-0.89),3 mg/kg组0.49(95%CI 0.15-1.64),5 mg/kg组0.46(95%CI 0.14-1.47)。
  • 平均生存时间:1 mg/kg组246分钟 vs 0 mg/kg组96分钟(p=0.04,t检验)。
  • 给药后1小时心肌收缩力(前负荷可募集每搏功):0.3 mg/kg组较伤后升高(p=0.003),1 mg/kg组升高(p<0.001),3和5 mg/kg组无变化,对照组降低(p=0.022)。

证据类型、等级与局限

  • 证据类型:动物实验(猪模型),在良好实验室规范下进行。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在无液体复苏情况下给予EES可降低多发伤合并失血性休克猪模型的死亡率并改善心肌收缩力,这些发现支持在人类创伤患者中开展临床试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although 17α-ethinyl estradiol-3-sulfate (EES) reduces mortality in animal models of controlled hemorrhage, its role in a clinically relevant injury model is unknown. We assessed the impact of EES in a swine model of multiple injuries and hemorrhage.

METHODS: The study was performed under Good Laboratory Practice, with 30 male uncastrated swine (25-50 kg) subjected to tibial fracture, pulmonary contusion, and 30% controlled hemorrhage for an hour. Animals were randomized to one of five EES doses: 0 (control), 0.3, 1, 3, and 5 mg/kg, administered postinjury. Subjects received no resuscitation and were observed for 6 hours or until death. Survival data were analyzed using Cox-proportional hazard regression. Left ventricular pressure-volume loops were used to derive preload recruitable stroke work as a measure of cardiac inotropy. Immediate postinjury preload recruitable stroke work values were compared with values at 1 hour post-drug administration.

RESULTS: Six-hour survival for the 0, 0.3, 1, 3, and 5 mg/kg groups was 0%, 50%, 33.3%, 16.7%, and 0%, respectively. Following Cox regression, the hazard (95% confidence interval) of death was significantly reduced in the 0.3 (0.22 [0.05-0.93]) and 1 (0.24 [0.06-0.89]) mg/kg groups but not the 3 (0.49 [0.15-1.64]) and 5 (0.46 [0.14-1.47]) mg/kg groups. Mean survival time was significantly extended in the 1 mg/kg group (246 minutes) versus the 0 mg/kg group (96 minutes) (p = 0.04, t test). At 1 hour post-drug administration, inotropy was significantly higher than postinjury values in the 0.3 and 1 mg/kg groups (p = 0.003 and p < 0.001, respectively). Inotropy was unchanged in the 3 and 5 mg/kg groups but significantly depressed in the control (p = 0.022).

CONCLUSION: Administration of EES even in the absence of fluid resuscitation reduces mortality and improves cardiac inotropy in a clinically relevant swine model of multiple injuries and hemorrhage. These findings support the need for a clinical trial in human trauma patients.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Abdou H, Morrison JJ, Edwards J, et al. An estrogen (17α-ethinyl estradiol-3-sulfate) reduces mortality in a swine model of multiple injuries and hemorrhagic shock. J Trauma Acute Care Surg. 2022. PMID: 34670961. doi:10.1097/TA.0000000000003434

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。